Leg Ulcers

3
Pipeline Programs
2
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

C
ColoplastAustralia - Mulgrave
4 programs
1
PhysiotullePhase 41 trial
BiatainN/A1 trial
Biatain AgN/A1 trial
Biatain IbuN/A1 trial
Active Trials
NCT00627094CompletedEst. Apr 2009
NCT00807664CompletedEst. Apr 2010
NCT00628004CompletedEst. Feb 2010
+1 more trials
ConvaTec
ConvaTecNJ - Bridgewater
2 programs
1
1
Aquacel® AgPhase 31 trial
Compression DevicePhase 21 trial
Active Trials
NCT00821431CompletedEst. Jun 2008
NCT01427491CompletedEst. Jan 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ColoplastPhysiotulle
ConvaTecAquacel® Ag
ConvaTecCompression Device
ColoplastBiatain Ag
ColoplastBiatain Ibu
ColoplastBiatain

Clinical Trials (6)

NCT01238419ColoplastPhysiotulle

Physiotulle vs Urgotul in the Treatment of Leg Ulcer

Start: Nov 2009Est. completion: May 2011
Phase 4Completed
NCT01427491ConvaTecAquacel® Ag

Compare Aquacel® Ag Versus Mepilex® Border Ag to Manage Bioburden in Leg Ulcers

Start: Aug 2011Est. completion: Jan 2012
Phase 3Completed
NCT00821431ConvaTecCompression Device

Compression Device Versus 4-layer Compression System

Start: May 2006Est. completion: Jun 2008
Phase 2Completed
NCT00807664ColoplastBiatain Ag

Biatain Ag vs Biatain in the Treament of Leg Ulcers

Start: Dec 2008Est. completion: Apr 2010
N/ACompleted
NCT00628004ColoplastBiatain Ibu

Safety Evaluation of Biatain Ibu in Painful Chronic Venous Leg Ulcers

Start: May 2008Est. completion: Feb 2010
N/ACompleted
NCT00627094ColoplastBiatain

Biatain Ibu vs. Biatain in Painful Chronic Venous Leg Ulcers

Start: Mar 2008Est. completion: Apr 2009
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space